AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02934009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal nuclear magnetic resonance (NMR)-profile measurement
Description: Nuclear magnetic resonance (NMR)-profile measurement of the dermis
Study NCT02096510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solu-Cortef
Description: administration by pump for minimum 2 weeks
Study NCT04057625 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: transthoracic ultrasound
Description: using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
Study NCT05588635 — intervention group
Intervention type: OTHER
Intervention: Identification of predictive factors
Description: Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
Study NCT01276171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Participants will place arterial line using ultrasound technique
Study NCT01276171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Participants will place arterial line using doppler technique
Study NCT01276171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: Participants will place arterial line using Palpation technique
Study NCT01688024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Study NCT01688024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT03723187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: experimental group use normal saline sealing tube
Study NCT03723187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline+heparin
Description: normal saline+heparin(Currently, Regular used in hospital)
Study NCT02322710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgotul: Low-adherent dressing
Study NCT00773838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
Study NCT00773838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
Study NCT00773838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
Study NCT05014633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EI skills training
Description: EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
Study NCT01494493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/allograft bone dowel
Description: The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
Study NCT01494493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/allograft bone dowel
Description: An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
Study NCT03800420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S first and then Placebo
Description: Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
Study NCT03800420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first and then BBT-401-1S
Description: Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
Study NCT02691585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: A raga will be played for 10 minutes \& data collected.
Study NCT02322710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TulleGras M.S.: Vaseline gauze
Study NCT03473093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: One group will receive oral pregabalin with morphine infusion
Study NCT03473093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One group will receive morphine infusion 20 microgram/kg/h
Study NCT00926692 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Subject will have blood draw.
Study NCT02096510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortef
Description: tablet treatment 2 ro 3 times per day for 14 days
Study NCT02096510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef
Description: tablet treatment 2 ro 3 times per day for 14 days
Study NCT04487262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac surgery
Description: Elective open heart surgery
Study NCT01124929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNTCP Category I treatment for 6 months
Description: 2H3R3Z3 E3 + 4H3R3
Study NCT01124929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNTCP Category I treatment for 9months
Description: 2H3R3Z3 E3 + 7H3R3
Study NCT02917564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
Description: After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
Study NCT02917564 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham - Participants will not recieve the Triamcinolone Acetonide
Description: Patients will be given a sham.
Study NCT02576145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT
Description: Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
Study NCT02576145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT
Description: Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
Study NCT02576145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
Study NCT02576145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
Study NCT02576145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KLH
Description: KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
Study NCT03267628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine as well as local anaesthetic in Blocks
Description: A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
Study NCT03267628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine as well as saline in Block
Description: 150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
Study NCT03267628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline intrathecal as well as saline in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
Study NCT03267628 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline intrathecal as well as saline in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
Study NCT02060916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ320
Description: Single-center pilot study, open label dose escalation design
Study NCT00117052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
Study NCT00878761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-100
Description: SC, single dose followed by multiple dose
Study NCT00179387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind-Body Psychotherapy Group
Description: Psycho-educational group
Study NCT00179387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind-Body Psychotherapy Group
Description: Spiritual-Existential Group
Study NCT02266680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Treatment Group
Description: The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
Study NCT01549769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Oral, once daily
Study NCT03267628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline intrathecal as well as local anaesthetic in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
Study NCT03267628 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline intrathecal as well as local anaesthetic in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
Study NCT01180569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles
Study NCT04424069 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgery
Description: Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
Study NCT05856604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
Study NCT05856604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling
Description: Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation.
Study NCT04090541 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rigid Tape
Description: Non-Elastic Tape
Study NCT04090541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology Tape
Description: Tape can be elongate only one direction
Study NCT04090541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical Tape
Description: Tape can be elongate only two direction
Study NCT03112174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally once daily
Study NCT03112174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally once daily
Study NCT03112174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally once daily
Study NCT01400022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Description: The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
Study NCT01400022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
Study NCT01294098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: 0.75 cc/kg of 1/4% Marcaine
Study NCT02414529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: Ergocalciferol 5000 units capsules given. 300,000 units PO once.
Study NCT02414529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02121665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic (Inersan)
Description: Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
Study NCT02121665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study NCT03101553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification
Description: Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
Study NCT03101553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Eight 15-minute sessions of progressive muscle relaxation (PMR).
Study NCT03112174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral tablet to match Venetoclax
Description: Administered orally once daily
Study NCT04567186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational senofilcon A C3 Multifocal Lens
Description: TEST
Study NCT04567186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A Multifocal Lens
Description: Dailies Total 1® Multifocal Contact Lens
Study NCT01592760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q SP
Description: air-Q SP placement for airway maintenance.
Study NCT01592760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: air-Q
Description: air-Q placement for airway maintenance.
Study NCT01592760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: i-gel placement for airway maintenance.
Study NCT01428401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Astragalus membranaceus
Description: Astragalus membranaceus ( AM) at a rate of 3 g three times per day
Study NCT01428401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: at a rate of 3 g three times per day
Study NCT01637142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.
Study NCT01637142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-LY2140023
Description: Administered IV.
Study NCT01637142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-LY404039
Description: Administered IV.
Study NCT01471080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: using RFA to treat cavernous hemangiomas
Study NCT01471080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy
Description: using hepatectomy to treat cavernous hemangiomas
Study NCT01989000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: 0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
Study NCT01989000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18]HX4
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Study NCT01908725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study NCT01989000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
Study NCT01989000 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
Study NCT01989000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.